FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed
This is the kind of transformation that changes lives, health trajectories, and futures
(F) Persistent rectovaginal fistula and BPC 157 therapy effect
Until the FDA completes that process, the committees recommendations do not change the regulatory status of these peptides
Relevant review points include the product page, BPC-157+TB-500 Blend COA, lot-level traceability, storage and handling documentation, product form, labeled amount, identity information, and supplier language